Methods and materials for identifying and treating membranous nephropathy
US-2024353404-A1 · Oct 24, 2024 · US
Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
US2017190791A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2017190791-A1 |
| Application number | US-201615363084-A |
| Country | US |
| Kind code | A1 |
| Filing date | Nov 29, 2016 |
| Priority date | Apr 26, 2010 |
| Publication date | Jul 6, 2017 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
First claim
Opening claim text (preview).
1 - 125 . (canceled) 126 . A therapeutic composition, comprising a pharmaceutically-acceptable carrier and an antibody or antigen-binding fragment thereof that exhibits binding specificity for an isolated aminoacyl-tRNA synthetase (AARS) polypeptide or an epitope selected from Table(s) 1-3, or Table(s) 4-6, and Table(s) 7-9, wherein the composition has a purity of at least about 90% on a protein basis and less than about 10 EU endotoxin/mg protein. 127 . The therapeutic composition of claim 126 , wherein the AARS polypeptide is selected from Table E7. 128 . The therapeutic composition of claim 126 , wherein the antibody or antigen binding fragment thereof is a monoclonal antibody. 129 . The therapeutic composition of claim 126 , wherein the antibody is a humanized antibody. 130 . The therapeutic composition of claim 126 , wherein the antibody or antigen-binding fragment thereof is an Fv fragment or a single chain Fv (sFv) polypeptide. 131 . The therapeutic composition of claim 126 , wherein the composition is a sterile, freeze-dried powder. 132 . The therapeutic composition of claim 126 , wherein the composition is a sterile injectable solution. 133 . The therapeutic composition of claim 126 , wherein the composition is buffered and comprises an isotonic agent. 134 . The therapeutic composition of claim 126 , wherein the composition is suitable for intravenous, intramuscular, subcutaneous, or intraperitoneal administration. 135 . The therapeutic composition of claim 126 , wherein the composition comprises a surfactant. 136 . The therapeutic composition of claim 126 , wherein the composition has a purity of at least about 95% on a protein basis. 137 . A method of modulating a cellular activity of a cell, or protein, comprising contacting the cell or protein with a therapeutic composition of claim 126 . 138 . The method of claim 137 , wherein the cellular activity is selected from cell proliferation, cell differentiation, cell signaling, gene transcription, angiogenesis, cell binding, metabolism, cytokine production or activity, cytokine receptor activity, and inflammation. 139 . The method of claim 137 , wherein the cell type is selected from the group consisting of pre-adipocytes, bone marrow, neutrophils, blood cells, hepatocytes, astrocytes, mesenchymal stem cells, and skeletal muscle cells. 140 . The method of claim 137 , wherein the cell is in a subject. 141 . The method of claim 140 , comprising treating the subject, wherein the subject has a condition associated with a neoplastic disease, an immune system disease or condition, an inflammatory disorder, an infectious disease, a metabolic disease, neuronal/neurological disease, a muscular/cardiovascular disease, a disease associated with aberrant hematopoiesis, a disease associated with aberrant angiogenesis, or a disease associated with aberrant cell survival.
Assignees
Inventors
Classifications
Drugs for disorders of the cardiovascular system · CPC title
Drugs for immunological or allergic disorders · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2017190791A1 cover?
- Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
- Who is the assignee on this patent?
- Atyr Pharma Inc, Pangu Biopharma Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07K16/40. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Jul 06 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).